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Introduction 
Somatostatin (somatotropin release-inhibiting hor-
mone, SRIH) is a hypothalamic hormone that was
originally characterized as a potent inhibitor of growth
hormone (GH) secretion [1]. In the pituitary, SRIH
also blocks the release of other hormones, such as thy-
rotrophin (TSH) [2] prolactin (PRL) [3] and
gonadotrophins [4,5]. At the periphery, SRIH is a mod-
ulator of endocrine and exocrine functions and regu-
lates differentiation and proliferation of normal and
tumor cells [6,7]. Within the nervous system, SRIH
acts as a neuromodulator with physiological effects on
neuroendocrine, motor and cognitive functions [8, 9].
The hypothalamic-pituitary-adrenal (HPA) axis is
an important control system and dynamic interface for
multiple physiological systems. Biochemically inter-
connected, it generates rhythmic hormone secretion.
The respective hormones, corticotrophin releasing hor-
mone (CRH), adrenocorticotropic hormone (ACTH)
and principle glucocorticosteroids (CORT; i.e. cortisol
in humans, corticosterone in rats), modulate their own
secretion through feed forward and feedback mecha-
nisms within the HPA axis and exert physiological
effects in target organs outside the HPA axis [10].
Corticotrophs (ACTH cells) are basophilic cells,
which produce proopiomelanocortin (POMC) and its
derivatives including ACTH, melanotropin (MSH) and
lipotropin (LPH). They represent approximately 15 to
20% of adenohypophysial cells [11]. ACTH release
from the anterior pituitary is regulated by a variety of
hormones and neuropeptides, by both cAMP depend-
ent and cAMP independent mechanisms [12]. SRIH or
its synthetic analogs can reduce circulating ACTH and
glucocorticoid levels in rats and humans in vivo
[13,14].
We have previously shown that multiple neonatal
treatment with SRIH-14 inhibited ACTH cells in the
pituitaries of neonatal female rats [15]. The aim of this
study was to examine whether this treatment has pro-
longed effects on the morphological characteristics of
pituitary ACTH cells of female rats extending to juve-
nile, peripubertal and adult periods of life.
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Abstract: The prolonged effects of neonatal SRIH-14 treatment on pituitary ACTH cells were investigated. Neonatal female
rats were injected subcutaneously with SRIH (20 μg/100g b.w.) every 12 hours for five consecutive days (3rd-7th day of life).
Groups of rats were then killed at the juvenile (16th day), peripubertal (38th day) or adult (80th day) stage. ACTH cells were
visualized using the peroxidase-antiperoxidase immunocytochemical procedure. Morphometry and stereology were used to
evaluate the ACTH-immunoreactive cell volume and volume density. The histological and immunocytochemical character-
istics of ACTH cells in neonatally treated females were changed in all examined periods. Thus, SRIH-14 induced signifi-
cant (p<0.05) decreases of ACTH cell volume in juvenile, peripubertal and adult rats by 26%, 39% and 14%, respectively,
in comparison to the corresponding controls. The volume density of ACTH cells was also diminished (by 31%; p<0.05) at
the juvenile stage in comparison with the corresponding controls. In peripubertal and adult rats, the volume densities of
ACTH cells were somewhat lower (17% and 14%, respectively), but the decreases did not reach statistical significance.
These findings suggest that neonatal treatment with SRIH-14 exerts a marked prolonged inhibitory effect on ACTH cell
morphology extending to the adult period of life. 
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Materials and methods
Experimental animals. Time-mated Wistar rats were housed
individually and maintained in a controlled environment (12 h
light: 12 h dark; 22±2°C), with feed food (“Subotica” Veterinars-
ki Zavod, Subotica, Serbia) and water freely available. Neonatal
(3rd - 7th day of life) female rats were injected subcutaneously
twice a day (8 AM and 8 PM) with 20 μg of SRIH-14 (S9129,
Sigma, St. Louis, Mo., USA) per 100 g b.w. for five consecutive
days. The dose regimen selected for SRIH-14 was based on that
of Rebuffat et al. [16] and modified for administration every 12
h instead of every 8 h. Control female rats received subcuta-
neously the equivalent volume of saline by the same schedule.
Groups of five animals were killed at 8 AM at the juvenile (16th
day), peripubertal (38th day) or adult (80th day) period of life. The
experimental protocols were approved by the Local Animal Care
Committee and conformed to the recommendations given in the
"Guide for the Care and Use of Laboratory Animals" (1996,
National Academy Press, Washington D.C.).
Light microscopy and immunocytochemistry. The pituitaries
were removed immediately after sacrifice and fixed in Bouin's
solution for 48 h at room temperature. After dehydration in an
ethanol gradient, organs were embedded in paraffin. Series of
seven sections (5 μm) of the pituitary cut through three tissue lev-
els (dorsal, middle and ventral portion) of the pars distalis were
used for immunostaining. For localization of ACTH cells the per-
oxidase-antiperoxidase method was used [17]. After deparaf-
finization and rehydration of sections, endogenous peroxidase
activity was blocked by incubation in methanol containing 0.3%
H2O2 for 15 min at room temperature, followed by rinsing in 0.1
M phosphate buffered saline (PBS; pH 7.4) for 5 min. The non-
specific background staining was reduced by incubation for 45
min with non-immune serum, i.e. normal porcine serum diluted
1:10 with PBS. The sections were then incubated overnight with
primary antibodies (1:1000 v/v rACTH antisera National Hor-
mone & Peptide Program, Harbor-Ucla Medical Center, Tor-
rance, CA 90509) for 1 h at room temperature. Subsequent to a 5
minute rinse in PBS, the sections were incubated with secondary
antibody (1:500 swine-anti-rabbit IgG, 45 min; DAKO A/S,
Glostrup, Denmark), rinsed for 5 min in PBS, incubated with rab-
bit-antiperoxidase serum (1:100; 45 min; DAKO A/S, Glostrup,
Denmark) and again rinsed in PBS. The antigen-antibody com-
plex was visualized by incubating the sections with chromogen
substrate, 0.05% 3,3-diaminobenzidine (DAB; Serva, Heidel-
berg, Germany) and 0.03% H2O2. The incubated sections were
counterstained with hematoxylin. Control sections were incubat-
ed with normal porcine serum without primary antisera. Digital
images were made on a DM RB photomicroscope (Leica, Wet-
zlar, Germany) with a JVCTK 1280E video camera (Leica) for
the acquisition and analysis of the images. 
Morphometry. The volume densities (VV) of the nuclei and the
cytoplasm of ACTH-immuno-reactive cells, as well as numerical
density (Na) of their nuclei per μm3 were measured using 50 test
areas of the pituitary gland at a magnification of X 1000, using
the multipurpose test system M42 [18]. The number of nuclei in
immunoreactive ACTH-cells per mm3 was estimated using the
formula of Weibel and Gomez [19] according to Weibel [18].
Since rat ACTH cells are mononuclear, the numerical density of
the nuclei (NV) corresponds to the number of cells per mm3.
NV = (k/β) × (Na3/2/Vv1/2)
On the basis of earlier karyometric studies [20], the shape
coefficient β of the pituitary cells was estimated to be 1.382. It
relates NV (number of cells counted per unit volume) to Na (num-
ber of cells counted per mm2) and VV (volume density) and
depends on the axial ratio of the nuclei. The volume densities of
ACTH-positive cells were expressed as percentages of total pitu-
itary cells in μm3.
Statistical analysis. The data obtained for each group were aver-
aged and the standard deviation was calculated. One-way analysis
of variance (ANOVA), followed by the multiple range test of Dun-
can was used for comparisons of the differences between the
groups. A probability value of 5% or less was considered statisti-
cally significant.
Results
Pituitary weight
Pituitary weight significantly increased from juvenile
to pubertal (by 124%) and from peripubertal to adult
period of life (by 53%) in control females. Multiple
neonatal SRIH-14 administration did not significantly
changed pituitary weight in any of examined periods
of life (Table 1).
Characteristics of immunopositive ACTH cells
ACTH cells of the control females in all examined
age groups were strongly immunocytochemically
stained. They were polygonal in shape with promi-
nent, often eccentrically located nuclei (Figs. 1a,b,c).
ACTH-positive cells were positioned throughout the
pituitary pars distalis and pars intermedia. It has
been noted that ACTH cells of adult females are larg-
er, with numerous longer cytoplasmatic extensions
and more homogenously immunostained cytoplasm
compared to those in immature animals (Fig. 1c).
ACTH cells in the pituitaries of juvenile, peripubertal
and adult females neonatally treated with SRIH-14
were smaller in size, and appeared less intensely
immunostained than those in the corresponding con-
trols (Fig. 1d,e,f).
Morphometric parameters of ACTH cells of
control females
Stereological analysis showed that volume of ACTH
cells did not differ from juvenile to peripubertal period
of life in the pituitaries of control female rats. Howev-
er, from peripubertal to adult period, a significant
increase (by 23%; p<0.05) was observed. The ACTH
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Table 1. Pituitary weight of control (C) and female rats in differ-
ent periods of life after neonatal SRIH-14 treatment. All values are
given as means ± SD. ap<0.05 vs. controls of previous age group.
cell volume was significantly higher in adult than in
juvenile period of life (by 25%; p<0.05; Fig. 2a). The
volume density of ACTH cells did not change from
juvenile till adult period of life (Fig. 2b).
Volume of ACTH cells in the pituitaries of juvenile
female rats neonatally treated with SRIH-14 was sig-
nificantly decreased (by 26%; p<0.05; Fig. 2a) com-
pared to the controls. Their volume density, i.e. the
percentage of ACTH cells per volume unit (mm3) of
total pituitary gland tissue, was also significantly
lower (31%; Fig. 2b).
In the pituitaries of peripubertal females neonatally
treated with SRIH-14, the volume of ACTH cells was
diminished (by 39%; p<0.05) when compared to the
corresponding controls (Fig. 2a). Their volume densi-
ty was 17% lower, but this difference did not reach sta-
tistical significance (Fig. 2b). 
Similarly, the volume of ACTH cells in the pitu-
itaries of adult females neonatally treated with SRIH-
14 was decreased by 14% (p<0.05. Fig. 2a) and their
volume density also tended to be lower (14%; p>0.05;
Fig. 2b).
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Fig. 1. Immunoreactive ACTH cells (arrows) in the pituitary pars distalis of female rats: control (a, b, c) and after neonatal SRIH-14 treat-
ment (d, e, f); at juvenile (a, d), peripubertal (b, e) and adult (c, f) periods of life. (PAP, 1256×).
Discussion
Multiple SRIH-14 doses applied in the neonatal period
of life caused significant inhibition of ACTH cells
when pituitaries were examined immediately after the
treatment [15]. Prolonged effects of SRIH-14 on
ACTH cells are largely unknown. In this study we
have shown that changes in the volume, volume densi-
ty and imunocytochemical appearance of ACTH cells
caused by SRIH-14 in the neonatal period of life
remained until adulthood.
Neonatally applied SRIH-14 did not cause the
changes in pituitary weights in any of examined peri-
ods of life. These results are in accordance with our
previous study [21]. Our earlier results [21] indicated
that intracerebroventricular (i.c.v.) administration of
SRIH-28 and the somatostatin analog, octreotide [22]
to adult rat females exerts marked inhibitory effects on
the morphometric and immunocytochemical parame-
ters of ACTH cells and their function. Recently, Silva
et al. [14] showed that the somatostatin analog,
SOM230, significantly inhibited CRH-stimulated pitu-
itary ACTH release in rats. Additionally, Luque et al.
[23] reported that SRIH decreased POMC mRNA and
ACTH release in the presence and absence of CRH in
primary mouse pituitary cell cultures, indicating that
SRIH can directly affect ACTH cells at the pituitary
level. Studies on somatostatin [23] or sstr2 [24] knock-
out mice showed that ACTH levels were significantly
increased in genetically altered compared to wild type
animals, suggesting a physiological role of SRIH on
ACTH secretion.
In rat pituitary cells, co-localization of all five
somatostatin receptors (sstr) with ACTH expressing
cells has been reported [25]. In another study, sst5
mRNA was found in 38% of normal corticotrophs,
and sstr2 in only 3% [26], whereas Mezey and
coworkers [27] demonstrated sst2 in a large popula-
tion and sstr5 in a small population of corticotrophs.
Somatostatin influences ACTH secretion in pituitary
cells in culture through inhibition of CRF-stimulated
adenyl cyclase activity, and by preventing stimulus-
elicited calcium influx [28] over sstr2 and sstr5
receptor subtypes but not over sstr1, sstr3 or sstr4
[29]. Reed et al. [30] reported that the neonatal rat
pituitary expresses the same complement of somato-
statin receptors (sstr 1-5) as the adult pituitary. They
also found that the expression of sst2 mRNA was age
dependent. Levels of sst2 mRNA were low in pitu-
itaries of 2-day-old animals, but thereafter rose pro-
gressively until adulthood. However, pituitaries of
neonatal animals expressed sst1, sst3, sst4, and sst5
mRNA with no significant ontogenic changes in
expression of these subtypes. SRIH-14, used in our
study, is known to bind to all five somatostatin recep-
tors with high affinity [7], and therefore had the
opportunity directly to affect ACTH cells in the
neonatal period of life. There is also some evidence
that SRIH could inhibit ACTH cells indirectly,
through inhibition of CRH release from the hypothal-
amus [31,7]. 
In our earlier study, neonatally applied SRIH-14 led
to a significant decrease of both, volume of ACTH
cells and their volume density by 39% and 33%,
respectively [15] in the pituitaries of neonatal females.
The decrease of these parameters sustained till the
juvenile period of life, observed in this study. After
SRIH-14 treatment, changes were noted in immunocy-
tochemical features of ACTH cells in the pituitaries of
juvenile females, as well. The cytoplasm was not uni-
formly stained, that is, immunolabeled granules were
clustered in groups and separated by unstained
regions. These results suggest an inhibitory effect of
neonatal SRIH-14 treatment. In the peripubertal period
the immunocytochemical appearance of ACTH cells
was similar to that seen in the juvenile period. Togeth-
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Fig. 2. a. The cellular volume (Vc; μm3) of ACTH-immunoposi-
tive cells of control (C) and experimental female rats after neona-
tal SRIH-14 treatment; b. volume density (VV) of immunoreactive
ACTH cells expressed as a percentage (%) of total adenohy-
pophyseal cell volume in control (C) and experimental female rats
after neonatal SRIH-14 treatment. All values are given as means ±
SD; n=5 animals per group; ap<0.05 between controls of different
age, bp<0.05 between SRIH-14 treated females and their corre-
sponding controls.
er with significantly decreased cell volumes, this sug-
gests that the inhibitory effect of neonatal SRIH-14
treatment persists in peripubertal females. In the pitu-
itaries of adult females neonatally treated with SRIH-
14, the ACTH cells appeared to be much more similar
to those in the controls, i.e. their cytoplasm was uni-
formly stained. The ACTH cell volume was however,
still significantly lower than that in the corresponding
controls. We have observed that the volume of ACTH
cells, in the pituitaries of control females, increased
from juvenile till adult period of life. The same pattern
was seen in the pituitaries of treated females. It must
be noted that although decreases in volume density,
that is, the percentage of ACTH cells in a volume unit
of total pituitary gland tissue did not reach statistical
significance in peripubertal and adult SRIH-14 treated
females, values tended to be lower than in the corre-
sponding controls. 
On the basis of our results we conclude that SRIH-
14, applied in the neonatal period of life, exerts pro-
longed inhibitory effects on immunocytochemical and
morphologic features of pituitary ACTH cells in
female rats. Changes inflicted in the neonatal period
remained until adulthood.
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